Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307

• Published in: JNCI : Journal of the National Cancer Institute Vol. 112; no. 7; pp. 698 - 707
• Main Authors: Gralow, Julie R, Barlow, William E, Paterson, Alexander H G, M'iao, Jieling L, Lew, Danika L, Stopeck, Alison T, Hayes, Daniel F, Hershman, Dawn L, Schubert, Mark M, Clemons, Mark, Van Poznak, Catherine H, Dees, Elizabeth C, Ingle, James N, Falkson, Carla I, Elias, Anthony D, Messino, Michael J, Margolis, Jeffrey H, Dakhil, Shaker R, Chew, Helen K, Dammann, Kim Z, Abrams, Jeffrey S, Livingston, Robert B, Hortobagyi, Gabriel N
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.07.2020; Oxford Publishing Limited (England)
• Subjects: Acids; Adjuvant therapy; Administration, Oral; Biomedical materials; Bisphosphonates; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - adverse effects; Bone Neoplasms - prevention & control; Bone Neoplasms - secondary; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Chemotherapy, Adjuvant; Clinical trials; Clodronic acid; Clodronic Acid - administration & dosage; Clodronic Acid - adverse effects; Confidence intervals; Dental implants; Diphosphonates - administration & dosage; Diphosphonates - adverse effects; Disease-Free Survival; Estrogens; Female; Humans; Ibandronic acid; Ibandronic Acid - administration & dosage; Ibandronic Acid - adverse effects; Infusions, Intravenous; Intravenous administration; Jaw; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteonecrosis; Post-menopause; Rank tests; Statistical analysis; Statistical tests; Subgroups; Survival; Survival Rate; Toxicity; Treatment Outcome; Zoledronic acid; Zoledronic Acid - administration & dosage; Zoledronic Acid - adverse effects

Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Onc...